AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
aceclidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| muscarinic receptors agonists/antagonists | 4314 | 827-61-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
cholinomimetic used to reduce intraocular pressure in glaucoma
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.663 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.119 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 3.090 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.837 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 85.110 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 54.880 | % | High | 1 |
| herg | hERG pIC50 | 4.409 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.080 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.228 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 71.990 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 | 35 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,CDK16,CDK4,CDK9,DYRK1A,EPHB4,MAP2K6,SIK2,STK33,SYK,TEK | 13 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.189 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 12.735 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 81.880 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.807 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 84.420 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 4.786 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 83.080 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 77.500 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 797.995 | uM | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 233.29 | 125.19 | 42 | 140 | 33756 | 90594509 |
| Instillation site irritation | 227.99 | 125.19 | 23 | 159 | 200 | 90628065 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EB08 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| ATC | S01EB58 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| FDA MoA | N0000000104 | Cholinergic Muscarinic Agonists |
| MeSH PA | D008916 | Miotics |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| FDA EPC | N0000175884 | Cholinergic Receptor Agonist |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
Related Drugs by ATC class:
S01EB Parasympathomimetics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.34 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 10052313 | March 24, 2034 | TREATMENT OF PRESBYOPIA |
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 11179328 | March 24, 2034 | TREATMENT OF PRESBYOPIA |
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 9844537 | March 24, 2034 | TREATMENT OF PRESBYOPIA |
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 12128036 | Oct. 8, 2039 | TREATMENT OF PRESBYOPIA |
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 12533347 | Oct. 8, 2039 | TREATMENT OF PRESBYOPIA |
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | 12414942 | March 15, 2044 | TREATMENT OF PRESBYOPIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 1.44% BASE | VIZZ | LENZ THERAP | N218585 | July 31, 2025 | RX | SOLUTION/DROPS | OPHTHALMIC | July 31, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 5.10 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | AGONIST | EC50 | 4.80 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M1 | GPCR | AGONIST | EC50 | 5 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M2 | GPCR | AGONIST | EC50 | 5.70 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M5 | GPCR | AGONIST | EC50 | 5.10 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 6.92 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 5.08 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D02750 | KEGG_DRUG |
| 6109-70-2 | SECONDARY_CAS_RN |
| 4044165 | VANDF |
| C0000948 | UMLSCUI |
| CHEBI:748028 | CHEBI |
| CHEMBL20835 | ChEMBL_ID |
| DB13262 | DRUGBANK_ID |
| C084650 | MESH_SUPPLEMENTAL_RECORD_UI |
| 14102 | IUPHAR_LIGAND_ID |
| 1367 | INN_ID |
| 0578K3ELIO | UNII |
| 1979 | PUBCHEM_CID |
| 2721766 | RXNORM |
| 44299 | MMSL |
| 005218 | NDDF |
| 005219 | NDDF |
| 0578K3ELIO | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VIZZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 84226-100 | SOLUTION/ DROPS | 14.66 mg | OPHTHALMIC | NDA | 25 sections |